School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW 2052, Australia.
J Alzheimers Dis. 2012;30(1):35-9. doi: 10.3233/JAD-2012-111955.
Selective Alzheimer's Disease Indicator-1 (Seladin-1) was originally identified by its down-regulation in the brains of Alzheimer's disease (AD) patients. Here, we re-examine existing data and present new gene expression data that refutes its role as a selective AD indicator. Furthermore, we caution against the use of the name "Seladin-1" and instead recommend adoption of the approved nomenclature, 3β-hydroxysterol Δ24-reductase (or DHCR24), which describes its catalytic function in cholesterol synthesis. Further work is required to determine what link, if any, exists between DHCR24 and AD.
选择性阿尔茨海默病标志物-1(Seladin-1)最初是通过其在阿尔茨海默病(AD)患者大脑中的下调而被鉴定出来的。在这里,我们重新检查了现有的数据,并提出了新的基因表达数据,这些数据驳斥了它作为选择性 AD 标志物的作用。此外,我们警告不要使用“Seladin-1”这个名称,而建议采用经过批准的命名法,即 3β-羟甾醇Δ24-还原酶(或 DHCR24),该命名法描述了其在胆固醇合成中的催化功能。需要进一步的工作来确定 DHCR24 和 AD 之间是否存在任何联系。